SPHERE Study for Hypereosinophilic Syndrome
A 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome.
- Sex at Birth: Any
- Age: Child (Birth - 17)
- Accepting Healthy People: No
- Type: Interventional / Device
- Trial Phase: Phase III
- Conditions Being Studied: Hypereosinophilic Syndrome
Study Purpose
The purpose of this study is to investigate the efficacy and safety of mepolizumab SC in children (aged 6 to 11 years) and adolescents (aged 12 to 17 years) with HES who are receiving standard of care (SoC) therapy. The primary objective of the study is to evaluate the efficacy of mepolizumab SC given every 4 weeks in participants aged 6 to 17 years with HES.
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00001509
- StudyID: 2021-0652
- ClinicalTrials.gov: NCT04965636
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422